Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05067231 · ClinicalTrials.gov registry record
CARBON: UAB Cardiovascular Research Biobank
A clinical trial of Obesity and Hypertension, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT05067231 is a study of Obesity and Hypertension that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 500 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05067231, a study of Obesity and Hypertension, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers undertaking a wide range of medical research.
Conditions Studied
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2030-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05067231
The ClinicalTrials.gov registry entry for NCT05067231 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (39% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Obesity appearing as the primary indexed condition, and to 0 interventions.
NCT05067231 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT05067231 about?
NCT05067231 is a clinical study titled "CARBON: UAB Cardiovascular Research Biobank". The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers unde...
What is the current status of trial NCT05067231?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2022-01-01. Estimated completion is 2030-01-01.
What conditions does trial NCT05067231 study?
This clinical trial studies the following conditions: Obesity, Hypertension, Diabetes, Cardiovascular Diseases, Natriuretic Peptides.
Who is sponsoring clinical trial NCT05067231?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05067231 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.